Enlivex Therapeutics Ltd Working Capital to Net Assets Ratio
Enlivex Therapeutics Ltd working capital to net assets ratio. Enlivex Therapeutics Ltd (ENLV) has a Working Capital to Net Assets ratio of 94.2% as of September 2025. Working capital of ILA16.47 Million (current assets of ILA19.50 Million minus current liabilities of ILA3.03 Million) is measured against net assets of ILA17.48 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Enlivex Therapeutics Ltd (2012–2024)
Working capital to net assets ratio of Enlivex Therapeutics Ltd from 2012 to 2024. This chart shows how Enlivex Therapeutics Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at 94.2%, reflecting working capital of ILA16.47 Million against net assets of ILA17.48 Million ILA. Explore investment intensity of Enlivex Therapeutics Ltd to see how much of total assets are deployed in long-term investments.
Enlivex Therapeutics Ltd Working Capital to Net Assets Ratio by Year (2012–2024)
Enlivex Therapeutics Ltd working capital to net assets ratio by year from 2012 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Enlivex Therapeutics Ltd from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Enlivex Therapeutics Ltd's balance sheet.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 94.1% | ILA22.19 Million | ILA23.59 Million | ILA25.99 Million | ILA3.80 Million | ▲ +2.0 pp |
| 2023 | 92.1% | ILA27.70 Million | ILA30.08 Million | ILA33.76 Million | ILA6.06 Million | ▲ +11.6 pp |
| 2022 | 80.4% | ILA45.72 Million | ILA56.84 Million | ILA52.33 Million | ILA6.61 Million | ▼ -15.7 pp |
| 2021 | 96.1% | ILA81.72 Million | ILA85.04 Million | ILA86.44 Million | ILA4.72 Million | ▲ +1.0 pp |
| 2020 | 95.1% | ILA33.75 Million | ILA35.49 Million | ILA38.12 Million | ILA4.37 Million | ▲ +2.6 pp |
| 2019 | 92.5% | ILA10.44 Million | ILA11.28 Million | ILA16.42 Million | ILA5.98 Million | ▼ -1.7 pp |
| 2018 | 94.2% | ILA9.15 Million | ILA9.71 Million | ILA10.28 Million | ILA1.13 Million | ▼ -5.8 pp |
| 2017 | 100.0% | ILA3.16 Million | ILA3.16 Million | ILA3.62 Million | ILA460.00K | ▲ +1.0 pp |
| 2016 | 99.0% | ILA8.61 Million | ILA8.70 Million | ILA10.54 Million | ILA1.93 Million | ▼ -0.7 pp |
| 2015 | 99.7% | ILA17.88 Million | ILA17.93 Million | ILA20.39 Million | ILA2.51 Million | ▼ -0.1 pp |
| 2014 | 99.8% | ILA30.61 Million | ILA30.67 Million | ILA32.88 Million | ILA2.28 Million | ▼ -0.1 pp |
| 2013 | 99.9% | ILA5.55 Million | ILA5.55 Million | ILA5.68 Million | ILA131.00K | ▼ -0.1 pp |
| 2012 | 100.0% | ILA75.00K | ILA75.00K | ILA156.00K | ILA81.00K | — |